Results 111 to 120 of about 117,203 (208)

Chronic traumatic encephalopathy in a neuropathologically confirmed Creutzfeldt–Jakob disease cohort

Brain Pathology, EarlyView.
Systematic neuropathological screening of 212 patients with Creutzfeldt–Jakob disease (55% women) identified chronic traumatic encephalopathy in three cases (1.4%), all men with a history of contact sports. These findings represent the first neuropathologically confirmed chronic traumatic encephalopathy cases reported in Spain.
Lluc Bertran, Iban Aldecoa, Arlène Sindikubwabo, Núria Vidal, Rafael Blesa, Mercè Martínez‐Corral, Carlos Nos, Verónica Santiago, Andrea González, Álex Iranzo, Christopher J. Nowinski, Ann C. McKee, Raquel Sánchez Valle, Laura Molina‐Porcel   +13 more
wiley   +1 more source

Unmasking Primary Carnitine Deficiency as a Mimic of Hypertrophic Cardiomyopathy [PDF]

Primary carnitine deficiency may mimic hypertrophic cardiomyopathy and be mistakenly attributed to genotype-negative sarcomeric protein dysfunction in hypertrophic cardiomyopathy.
Stafford, Sarah G., Sivak, Joseph A., Jensen, Brian C., Weickert, Thelsa T., Sang, Charlie J.   +4 more
core   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Allele-specific dysregulation of lipid and energy metabolism in early-stage hypertrophic cardiomyopathy

Journal of Molecular and Cellular Cardiology Plus
Introduction: Hypertrophic cardiomyopathy (HCM) results from pathogenic variants in sarcomeric protein genes that increase myocyte energy demand and lead to cardiac hypertrophy.
Arpana Vaniya, Anja Karlstaedt, Damla Gulkok, Tilo Thottakara, Yamin Liu, Sili Fan, Hannah Eades, Styliani Vakrou, Ryuya Fukunaga, Hilary J. Vernon, Oliver Fiehn, M. Roselle Abraham   +11 more
doaj   +1 more source

Role of Septal Myectomy in Pediatric Hypertrophic Cardiomyopathy [PDF]

Hypertrophic cardiomyopathy is a prevalent cause of sudden cardiac death among young people. This distinctive genetic condition can manifest at any age from infancy to adulthood.
Sameh M. Said
core   +1 more source

Emerging insights into amino acid metabolism in the heart: implications for cardiovascular diseases and therapeutic targeting

British Journal of Pharmacology, EarlyView.
As a metabolically versatile organ, the heart is capable of generating energy from a wide range of substrates. Although fatty acid and glucose metabolism in the heart have been extensively studied, the contribution of amino acid metabolism to cardiac physiology and disease is gaining increasing attention.
Tayyiba Azam, Hongyuan Zhang, Min Zi, Chen Chen, Junfang Wu, Andreas Papapetropoulos, Xin Wang   +6 more
wiley   +1 more source

Targeting CKIP‐1 for Disease Therapy: Cellular Functions, Molecular Networks, and Clinical Potential

Cell Proliferation, EarlyView.
CKIP‐1, as a scaffold protein with special structural domains, treats related diseases through multiple emerging targeted technologies.
Xin Huang, Shijie Lv, Lejia Li, Jirong Xie, Zhengguo Cao   +4 more
wiley   +1 more source

HYPERTROPHIC CARDIOMYOPATHY IN MULTIMORBIDITY [PDF]

, 2016
Aspects of diagnosis, difficulties in the diagnosis and optimal therapeutic strategies in patient with hypertrophic cardiomyopathy and comorbid conditions such as arterial hypertension, ischemic heart disease, dyslipidemia, diabetes mellitus type 2 ...
A. I. Lakhonina, N. A. Vodyanitska, N. V. Makienko, A. V. Filatova   +3 more
core  

SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background and Aim Fabry disease (FD) is frequently complicated by renal impairment and cardiovascular events; however, evidence on sodium–glucose cotransporter‐2 inhibitors (SGLT2i) in this population is scarce. Accordingly, we assessed the association between SGLT2i exposure and cardiovascular outcomes in adults with FD. Methods We conducted
Leandra Serio, Michele Rossi, Amir Askarinejad, Enrico Tartaglia, Tommaso Bucci, Enrica Marrone, Dinesh K. Kalra, Claudio Ferri, Gregory Y. H. Lip   +8 more
wiley   +1 more source